<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225653</url>
  </required_header>
  <id_info>
    <org_study_id>Latano-2</org_study_id>
    <secondary_id>2010-022433-29</secondary_id>
    <nct_id>NCT01225653</nct_id>
  </id_info>
  <brief_title>Topical Application of Latanoprost in Diabetic Retinopathy</brief_title>
  <acronym>Latano-2</acronym>
  <official_title>Topical Application of Latanoprost in Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized double-blinded two-year intervention study with topical application of latanoprost
      or placebo eye drops in patients with diabetic retinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to study if a sustained contraction of pathologically dilated
      retinal arterioles can be obtained. Retinal arteriolar diameter and the diameter response to
      increased blood pressure is studied using the Dynamic Vessel Analyzer (Imedos, Germany.

      The secondary objective is to study whether the intervention can halt the development of
      diabetic retinopathy, which is assessed by optical coherence tomography (OCT) scanning and
      fundus photography.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The diameter of retinal arterioles</measure>
    <time_frame>24 months</time_frame>
    <description>The diameter of retinal arterioles will be assessed using the Dynamic Vessel Analyzer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The severity of diabetic retinopathy</measure>
    <time_frame>24 months</time_frame>
    <description>Severity of diabetic retinopathy will be measured by optical coherence tomography (OCT) scanning and fundus photography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical treatment with latanoprost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>Topical application</description>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-36 years old

          -  Diabetes mellitus with retinopathy

        Exclusion Criteria:

          -  Pregnancy

          -  Previous ocular disease other than diabetic retinopathy

          -  General disease with possible influence on the eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toke Bek, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Ophthalmology, Århus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, Århus University Hospital</name>
      <address>
        <city>Århus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Latanoprost</keyword>
  <keyword>vasodilation</keyword>
  <keyword>diabetic retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

